接受多替拉韦与达芦那韦联合抗逆转录病毒方案治疗的早期HIV感染者生殖道HIV-1-RNA与总HIV-1-DNA载量比较
本研究为ANRS169 OPTIPRIM-2试验的生殖道亚组研究,比较早期HIV感染者接受替诺福韦/恩曲他滨/多替拉韦(18例)或替诺福韦/恩曲他滨/达芦那韦/可比司他(19例)方案后精液中HIV-RNA与总HIV-DNA的动态变化。结果显示两方案在各时间点精液血浆HIV-RNA不可测比例相似,第48周多替拉韦组与达芦那韦组可测HIV-RNA比例分别为15.4%和28.6%、可测HIV-DNA比例分别为9.1%和14.3%,无显著差异。
要点
- 第0周至第2周精液血浆HIV-RNA下降1 log10 copies/mL。
- 第48周多替拉韦组与达芦那韦组可测精液HIV-RNA比例分别为15.4%和28.6%,无显著差异。
- 第48周多替拉韦组与达芦那韦组可测精液HIV-DNA比例分别为9.1%和14.3%,无显著差异。
核心结论
- 以多替拉韦为基础的方案在早期HIV感染时启动可降低HIV-RNA和HIV-DNA,与以达芦那韦为基础的对照组相比无差异。
- 尽管早期HIV感染后精液中病毒清除似乎比慢性HIV感染更慢(因病毒载量高),早期启动多替拉韦治疗可使精液中病毒颗粒和感染细胞大幅下降,有效降低早期HIV感染期间的高传播风险。
研究设计与样本
- ANRS169 OPTIPRIM-2试验的生殖道亚组研究,18例受试者接受替诺福韦/恩曲他滨/多替拉韦,19例接受替诺福韦/恩曲他滨/达芦那韦/可比司他作为早期HIV感染一线联合抗逆转录病毒治疗。
主要发现
- 第0周至第2周精液血浆HIV-RNA下降1 log10 copies/mL。
- 两方案在各时间点精液血浆HIV-RNA不可测比例相似。
- 第48周总体8例患者精液中仍可测到HIV-RNA或HIV-DNA;多替拉韦组和达芦那韦组可测HIV-RNA比例分别为15.4%和28.6%,可测HIV-DNA比例分别为9.1%和14.3%,无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dolutegravir is a widespread integrase strand-transfer inhibitor (INSTI) recommended for treatment of primary HIV infection (PHI). PHI is a high-risk stage for sexual transmission because of the high viral load in semen. Yet dolutegravir concentrations in semen are lower than in blood during chronic treatment. OBJECTIVES: To compare the kinetics of HIV-RNA and total HIV-DNA in the genital compartment in subjects receiving either tenofovir/emtricitabine/dolutegravir or tenofovir/emtricitabine/darunavir/cobicistat as a first-line combined ART (cART) at the time of PHI. PATIENTS AND METHODS: Eighteen subjects receiving tenofovir/emtricitabine/dolutegravir and 19 receiving tenofovir/emtricitabine/darunavir/cobicistat enrolled in the ANRS169 OPTIPRIM-2 trial participated in the genital substudy. RESULTS: Between week (W) 0 and W2 HIV-RNA in seminal plasma (SP) decreased by 1 log10 copies/mL. Undetectable SP HIV-RNA was achieved in similar proportions between the two regimens at each timepoint. Overall, eight patients still presented detectable HIV-RNA or HIV-DNA in semen at W48; 15.4% and 28.6% presented detectable HIV-RNA and 9.1% and 14.3% presented detectable HIV-DNA in dolutegravir- and darunavir-based cART groups, respectively, with no significant difference. CONCLUSIONS: For the first time, to the best of our knowledge, we showed that a dolutegravir-based regimen initiated as soon as PHI reduces HIV-RNA and HIV-DNA with no difference compared with a control group receiving a darunavir-based regimen. Although the viral purge in semen seems longer after treatment in PHI than CHI, due to high viral loads, early dolutegravir-based treatment initiation permits a major decay of both viral particles and infected cells in semen, efficiently reducing the high risk of transmission during PHI.
引用
- Mariaggi AA, Bauer R, Charre C, et al. HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection. J Antimicrob Chemother. 2022. PMID: 35195692. doi:10.1093/jac/dkab427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。